rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells
Source abstract
Abstract
Abstract Despite strides in immunotherapy, glioblastoma multiforme (GBM) remains challenging due to low inherent immunogenicity and suppressive tumor microenvironment. Converting “cold” GBMs to “hot” is crucial for immune activation and improved outcomes. This study comprehensively characterized a therapeutic vaccination strategy for preclinical GBM models. The vaccine consists of Mannan‐BAM‐anchored irradiated whole tumor cells, Toll‐like receptor ligands [lipoteichoic acid (LTA), polyinosinic‐polycytidylic acid (Poly (I:C)), and resiquimod (R‐848)], and anti‐CD40 agonistic antibody (rWTC‐MBTA). Intracranial GBM models (GL261, SB28 cells) are used to evaluate the vaccine efficacy. A substantial number of vaccinated mice exhibited complete regression of GBM tumors in a T‐cell‐dependent manner, with no significant toxicity. Long‐term tumor‐specific immune memory is confirmed upon tumor rechallenge. In the vaccine‐draining lymph nodes of the SB28 model, rWTC‐MBTA vaccination triggered a major rise in conventional dendritic cell type 1 (cDC1) 12 h post‐treatment, followed by an increase in conventional dendritic cell type 2 (cDC2), monocyte‐derived dendritic cell (moDC), and plasmacytoid dendritic cell (pDC) on Day 5 and Day 13. Enhanced cytotoxicity of CD4+ and CD8+ T cells in vaccinated mice is verified in co‐culture with tumor cells. Analyses of immunosuppressive signals (T‐cell exhaustion, myeloid‐derived suppressor cells (MDSC), M2 macrophages) in the GBM microenvironment suggest potential combinations with other immunotherapies for enhanced efficacy. In conclusion, the authors findings demonstrate that rWTC‐MBTA induces potent and long‐term adaptive immune responses against GBM.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Glioma Diagnosis and Treatment · Immunotherapy and Immune Responses · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Neuro‐Oncology Branch National Cancer Institute National Institutes of Health Bethesda Maryland 10022 USA
NE1 Inc. New York NY 10022 USA
Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health 9000 Rockville Pike Bethesda MD 20892 USA
John Theurer Cancer Center HUMC Hackensack Meridian School of Medicine 92 2nd St Hackensack NJ 07601 USA
Department of Medical Biology Faculty of Science University of South Bohemia České Budějovice 37005 Czech Republic
References (40)
Show source-provided references
1. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
2. 10.3390/biomedicines1002042710.3390/biomedicines10020427 ↗
3. 10.1177/175883592093761210.1177/1758835920937612 ↗
4. 10.1002/cam4.37110.1002/cam4.371 ↗
5. 10.1080/21645515.2020.178269210.1080/21645515.2020.1782692 ↗
6. 10.3389/fnins.2021.66206410.3389/fnins.2021.662064 ↗
7. 10.1038/s41568-019-0224-710.1038/s41568-019-0224-7 ↗
8. 10.1038/s41571-018-0003-510.1038/s41571-018-0003-5 ↗
9. 10.1158/1078-0432.CCR-18-162710.1158/1078-0432.CCR-18-1627 ↗
10. 10.1158/1078-0432.CCR-10-255710.1158/1078-0432.CCR-10-2557 ↗
11. 10.1016/j.annonc.2021.08.215310.1016/j.annonc.2021.08.2153 ↗
12. 10.1038/s41416-023-02327-610.1038/s41416-023-02327-6 ↗
13. 10.1186/s12967-018-1507-610.1186/s12967-018-1507-6 ↗
14. 10.1001/jamaoncol.2022.537010.1001/jamaoncol.2022.5370 ↗
15. 10.1080/14760584.2016.121876210.1080/14760584.2016.1218762 ↗
16. 10.1038/s41577-018-0088-110.1038/s41577-018-0088-1 ↗
17. 10.1038/ni.246710.1038/ni.2467 ↗
18. 10.1016/j.it.2017.06.00810.1016/j.it.2017.06.008 ↗
19. Cabeza‐Cabrerizo M. · Dendritic Cells Revisited. Annu Rev Immunol · 2021 · 39 · 166
20. 10.1158/2326-6066.CIR-22-009810.1158/2326-6066.CIR-22-0098 ↗
21. Medina R. · Adv. Ther. (Weinh) · 2020 · 3
22. 10.1097/01.cji.0000436722.46675.4a10.1097/01.cji.0000436722.46675.4a ↗
23. 10.1186/s13046-023-02744-810.1186/s13046-023-02744-8 ↗
24. 10.1093/noajnl/vdad00910.1093/noajnl/vdad009 ↗
25. 10.1016/j.trecan.2022.12.00810.1016/j.trecan.2022.12.008 ↗
26. 10.1186/1479-5876-2-4010.1186/1479-5876-2-40 ↗
27. 10.1038/s41598-017-12584-010.1038/s41598-017-12584-0 ↗
28. 10.1158/2326-6066.CIR-16-015610.1158/2326-6066.CIR-16-0156 ↗
29. 10.1080/2162402X.2018.150113710.1080/2162402X.2018.1501137 ↗
30. 10.3390/cancers1301001910.3390/cancers13010019 ↗
31. Luksik A. S. · Cancers (Basel) · 2023 · 15
32. 10.1111/j.1365-2567.2006.02384.x10.1111/j.1365-2567.2006.02384.x ↗
33. 10.1084/jem.2009024710.1084/jem.20090247 ↗
34. 10.1007/s00262-011-1014-610.1007/s00262-011-1014-6 ↗
35. 10.1002/eji.20032379710.1002/eji.200323797 ↗
36. 10.1038/nature0332610.1038/nature03326 ↗
37. 10.4049/jimmunol.200096510.4049/jimmunol.2000965 ↗
38. 10.1007/s00262-010-0833-110.1007/s00262-010-0833-1 ↗
39. Antonios J. P. · Neuro Oncol · 2017 · 19 · 796
40. 10.1002/adtp.20200004410.1002/adtp.202000044 ↗